Ang II Receptors
The effect of Ang II on cardiac tissue is related to the activation of 2 specific receptors, AT 1 and AT 2 . 3, 4 The AT 1 receptor has 2 subtypes: AT 1A and AT 1B . 5 AT 1A receptors are major blood pressure regulators and potent growth stimulators in cardiomyocytes in vivo, whereas AT 1B receptors are involved in the control of vascular tone when AT 1A receptors are absent. 6 Ang II receptors are 7-transmembrane domain receptors whose primary structures have been established by molecular cloning. [7] [8] [9] The activation of the receptor is coupled to several intracellular proteins, starting with a G protein. 10 The receptor domains that couple to G proteins involve the second and third cytosolic loops and the proximal segment of the carboxy-terminal domain. 10 -12 In the rat, AT 1A , AT 1B , and AT 2 receptors are located on chromosomes 17, 2, and X, respectively. 11 Samyn et al 13 have demonstrated that cardiac AT 1 receptor gene expression is relatively unchanged during fetal and newborn life and that AT 2 receptor mRNA expression is high during fetal development and decreases rapidly after birth. Administration of Ang II to a rat whole embryo culture causes an increase in ventricular growth and myocyte hypertrophy, whereas the AT 1 receptor antagonist losartan and the AT 2 receptor antagonist PD123319, when added together to this preparation, attenuate ventricular development and induce cardiac loop inversions. 14 Exposure of AT 1A and AT 1B receptors to Ang II is followed by translocation of the receptor to intracellular vesicles. 15 Internalization of the Ang II-AT 1 receptor complex occurs with a half-life of Ͻ2 minutes. 16 Unlike AT 2 receptors, which are not internalized, 17 AT 1 receptors appear to cycle continuously between endosomal vesicles and the plasma cell membrane. 18 In agreement with this contention, AT 1 receptors in rat myocytes have been localized in the sarcolemma, T tubules, and nuclei. 19 Internalized Ang II is either degraded in the cell or exerts intracellular effects. In support of the latter, evidence is available that Ang II couples to a nuclear binding site 20 and that binding of Ang II to a chromatin high-affinity receptor leads to a conformational change in chromatin. 21 Recently, a soluble high-affinity binding protein for Ang II was localized in the cytosol of neonatal rat cardiac cells with a mass of 78 kDa. 22 Intracellular dialysis of Ang II in adult rat myocytes reduces cell communication, an effect abolished by intracellular administration of losartan. 23 Similarly, the intracellular actions of Ang II in vascular smooth muscle cells are suppressed by the AT 1 receptor antagonist candesartan. 24 These findings indicate that there may be a functional intracellular Ang II receptor similar to the AT 1 receptor, although further studies are necessary to clarify this point.
The signaling mechanism of Ang II receptors is quite well defined. Activation of AT 1 receptors results in the initiation of a variety of events, such as the stimulation of phospholipase C, with subsequent activation of protein kinase C (PKC) and release of Ca 2ϩ from intracellular depots. In addition, tyrosine kinase and mitogen-activated protein kinase are phosphorylated. 25 Interestingly, AT 2 receptor blockade increments the early signals of AT 1 receptor-mediated cardiac growth responses in the hypertrophied rat heart, 26, 27 suggesting that AT 2 receptors counteract the effects of AT 1 receptors. The establishment of left ventricular hypertrophy in spontaneously hypertensive rats is associated with increased expression of AT 1A and AT 1B receptors. 28 AT 2 receptors are upregulated by interleukin-1␤ and insulin, whereas an increase in intracellular Ca 2ϩ -activated PKC as well as in several growth factors (epidermal growth factor, nerve growth factor, and platelet-derived growth factor) induces a downregulation of AT 2 receptors. 29 AT 2 receptors activate the kinin/NO/cGMP system and stimulate protein tyrosine phosphatase and serine/ threonine phosphatase. 29 Protein tyrosine phosphatase stimulation inactivates AT 1 receptor-activated mitogen-activated protein kinase, 30 and this may explain the above interaction between AT 1 and AT 2 receptors. In addition, activation of extracellular signal-regulated kinase, which underlies the mitogenic or hypertrophic response after AT 1 receptor stimulation, can be reversed by AT 2 receptor-mediated stimulation of serine/threonine phosphatase 2A. 31 Interaction between AT 1 and AT 2 receptors represents a topic of interest, particularly to heart pathology. In pigs, for instance, reduction in infarct size induced by AT 1 receptor blockade occurs through a signal cascade involving AT 2 receptor activation, bradykinin, and prostaglandins. 32 In infarcted rats, the beneficial effects of AT 1 receptor antagonists on left ventricular end-diastolic and end-systolic volumes, ejection fraction, interstitial fibrosis, and myocyte hypertrophy are suppressed by simultaneous intravenous administration of an AT 2 receptor antagonist. 33, 34 Similarly, AT 2 receptors in the failing hearts of cardiomyopathic hamsters counteract the AT 1 receptor-induced progression of interstitial fibrosis. 35 In this regard, it is of interest that the density of AT 2 receptors in the perivascular, endocardial, and infarcted areas of hearts of patients with dilated cardiomyopathy or severe ischemic heart disease is greatly increased, particularly in areas of collagen deposition or fibrosis. 36 Moreover, Ͼ80% of the Ang II receptors in right atrial biopsies obtained from patients with coronary disease is of the AT 2 type, and these receptors are mainly associated with fibrous tissue. 37 Recently, it was found that Ang II induces apoptosis in cultured neonatal rat ventricular myocytes through the activation of AT 1 receptors and PKC. 38 Because p53 increased the expression of angiotensinogen in these cells, it was postulated that p53 induces apoptosis through the stimulation of Ang II release from myocytes and subsequent AT 1 receptor activation. 38 However, apoptosis has also been attributed to AT 2 receptor stimulation and its second messenger ceramide. 39, 40 Studies in transgenic animals have shed further light on the importance of AT 1A and AT 2 receptors in cardiac function, growth, and remodeling. [41] [42] [43] [44] AT 1A receptor knockout mice display less left ventricular remodeling and greater survival after myocardial infarction. 43 Disruption of the mouse AT 2 receptor gene resulted in a significant increase in blood pressure, 42 whereas cardiac-specific overexpression of AT 2 receptors in mice attenuated the AT 1 receptor-mediated pressor and chronotropic effects. 44 Furthermore, in humans, the AT 1 receptor A/C 1166 polymorphism and the A/G 1675 gene variant of the AT 2 receptor modulate left ventricular hypertrophy. 45, 46 In summary, activation of cell-surface AT 1 receptors is responsible for most of the Ang II-mediated effects in the heart, specifically those on growth and remodeling, and some of these effects are counteracted by AT 2 receptor activation. In addition, Ang II may exert effects through binding to intracellular AT 1 receptor-like proteins.
Ang II Synthesis in the Heart Under Normal Conditions
Ang II has been demonstrated in cardiac tissue by many authors. [47] [48] [49] [50] Although its levels in the heart are several times higher than those measured concomitantly in plasma, this does not necessarily imply that Ang II is synthesized in the heart by locally synthesized renin, angiotensinogen, and ACE. First, Ang II present in the heart may have been taken up from the circulation via AT 1 receptor-mediated endocytosis, 51 and second, if local Ang II synthesis has occurred, it may depend on RAS components that are also taken up from the circulation. To quantify angiotensin uptake from plasma, the tissue and plasma levels of endogenous and radiolabeled Ang I and Ang II were measured during infusions of 125 I-labeled Ang I and Ang II. 50 The results indicated that at steady state, the cardiac concentrations of 125 I-Ang I are Ͻ5% of its levels in plasma, whereas the concentrations of cardiac 125 I-Ang II are Ϸ90% of plasma 125 I-Ang II. At the same time, the cardiac tissue concentration of endogenous Ang I was similar to the plasma concentration of endogenous Ang I, whereas the tissue concentration of endogenous Ang II was 4 to 5 times higher than the plasma concentration of endogenous Ang II. From these data, it can be calculated that Ͼ90% of cardiac tissue Ang I is synthesized at tissue sites and is not derived from the circulation. Furthermore, Ͼ75% of cardiac tissue Ang II is also synthesized at tissue sites, and its source is in situ-synthesized Ang I rather than plasma Ang I. Thus, these findings clearly support the concept of angiotensin synthesis at cardiac tissue sites.
Renin mRNA levels in normal hearts are low or undetectable, [52] [53] [54] and the cardiac levels of renin, Ang I, and Ang II decrease in parallel with the plasma levels of these RAS components to levels close to or below the detection limit after a bilateral nephrectomy. 47, 55 Furthermore, renin and angiotensins cannot be demonstrated in the perfusate of the isolated Langendorff-perfused rat heart 56, 57 or in the supernatant of serum-deprived neonatal rat cardiomyocytes. 58, 59 Therefore, it appears that the renin responsible for cardiac angiotensin generation is renin of renal origin that reaches the heart via the circulation. Renin may enter the heart either through diffusion in the interstitial space 56, 60 or through binding to renin receptors. [61] [62] [63] [64] The source of angiotensinogen in the heart is currently unknown. Although angiotensinogen mRNA can be demonstrated in the heart, its cardiac levels are Ͻ0.1% of the angiotensinogen mRNA levels in the liver. 53, 65, 66 Moreover, the isolated Langendorffperfused rat heart does not release angiotensinogen, 56 nor could angiotensinogen be demonstrated in the supernatant of serum-deprived neonatal rat cardiomyocytes and fibroblasts. 59 Thus, evidence for the production of angiotensinogen at cardiac tissue sites is not available, and most likely, the majority of angiotensinogen in the heart is also derived from the circulation. The angiotensinogen concentrations present in cardiac tissue are compatible with the idea that angiotensinogen diffuses freely from the blood compartment into the interstitial space. 47, 60 Studies in a modified version of the rat Langendorff-perfused heart, allowing the separate collection of coronary effluent and interstitial transudate, showed that angiotensinogen, when added to the perfusion buffer, rapidly entered the interstitial space. 56 At steady state, its levels in interstitial fluid and coronary effluent were comparable. Evidence for binding of angiotensinogen to cardiac membranes could not be obtained. 47 Local synthesis of ACE at cardiac tissue sites does occur beyond doubt. ACE mRNA is readily detectable in the heart, 67, 68 and ACE has been demonstrated in the heart by autoradiography, 69 as well as by measurement of its activity in cardiac homogenates. 68 Moreover, Ang I is converted to Ang II in the isolated perfused rat heart. 57 Normally, the presence of ACE in the heart is limited to the coronary vascular endothelial cells and the endocardium. 70 In summary, Ang II synthesis occurs at cardiac tissue sites and depends on renin and angiotensinogen taken up from the circulation.
Ang II Synthesis in the Heart Under Pathological Conditions
Despite the lack of renin and angiotensinogen synthesis at cardiac tissue sites under normal conditions, it is not unlikely that the renin and angiotensinogen genes at these sites are switched on in response to pathological conditions. Cardiac Ang II levels increase after a myocardial infarction and in response to pressure and volume overload. 49, 71 Most studies investigating the cardiac RAS under pathological conditions have determined changes at the mRNA level. In view of the low to undetectable levels of renin and angiotensinogen mRNA in control hearts, as well as the uncertainties with regard to transcriptional regulation, it is difficult to establish the value of increased mRNA levels in the diseased heart. Pieruzzi et al 72 have described increases in renin mRNA in the rat heart in response to volume overload, whereas Iwai et al 66 were unable to confirm these findings. No change in cardiac angiotensinogen mRNA was found in the volumeoverload model. 54, 66 In contrast, Lindpaintner et al 65 reported a transient activation of angiotensinogen mRNA in the noninfarcted left ventricle of rats after a coronary artery ligation. Part of these discrepancies might be related to the inflammatory response that will occur after myocardial infarction but not after the induction of volume overload. Ang II, through its effect on prostaglandin synthesis, 73 will affect this response. Detailed information on myocardial renin-angiotensinogen dynamics during pressure overload-induced cardiac hypertrophy and after myocardial infarction has been obtained by Heller et al 60 and Hirsch et al. 74 They found cardiac renin to vary directly with plasma renin under all circumstances. Similarly, the rise in cardiac renin occurring in subjects with end-stage heart failure was accompanied by a parallel increase in plasma renin. 62 Thus, on the basis of renin protein measurements in cardiac tissue, no evidence was obtained for significant cardiac renin production under pathological conditions. It is not known whether the uptake of circulating renin is altered in infarcted or hypertrophying areas of the diseased heart. Demonstration of significant angiotensinogen production in the heart under pathological conditions is even more difficult, because increased consumption by renin may mask local production. Indeed, decreased rather than increased angiotensinogen levels were found in failing human hearts, 62 whereas in infarcted rat hearts or in rat hearts that had been exposed to pressure overload, no changes in angiotensinogen content were observed. 60, 74 Finally, with regard to ACE, the findings on changes in mRNA levels in diseased hearts are in full agreement with the findings on changes in its protein levels under these conditions. Cardiac tissue ACE increases after myocardial infarction as well as during pressure and volume overload-induced left ventricular hypertrophy. [67] [68] [69] 72 Under these conditions, the localization of ACE may no longer be limited to the endothelium. In humans, after myocardial infarction, ACE can be detected in the remaining viable cardiomyocytes near the infarct scar of the aneurysmal left ventricle as well as in fibroblasts, vascular smooth muscle cells, and macrophages in the scar area itself. 75 In rats, after coronary occlusion, ACE was demonstrated in fibroblasts in the healthy hypertrophying part of the heart. 76 Taken together, cardiac Ang II levels increase under pathological conditions because (1) the elevated renin levels in blood plasma under these circumstances allow the heart to sequester more renin from the circulation, and (2) the cardiac ACE levels are increased. The rise in cardiac Ang II generation may result in decreased cardiac angiotensinogen levels.
Stretch-Mediated Ang II Release From
Myocytes: Is Ang II Synthesized Intracellularly?
According to several studies, serum-deprived cardiomyocytes release angiotensins into the culture medium. [77] [78] [79] This is remarkable, in view of the fact that cardiomyocytes do not synthesize renin or angiotensinogen in measurable quantities. 59 One possibility is that the cells have sequestered renin and/or angiotensinogen from the serum-containing medium that is normally used to culture the cells. 63 The Ang I and II levels in the medium showed huge variations, from Ͻ10 to Ͼ1000 fmol/mL. Part of these discrepancies may be due to the fact that angiotensins were sometimes measured by direct radioimmunoassays (ie, without prior purification and/or separation from material cross-reacting with the Ang I and II antibodies applied in these assays). This approach will lead to an overestimation of the true angiotensin levels or even to the
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Ang II and the Heartdetection of angiotensins in medium that does not contain angiotensins. It should also be kept in mind that in view of the cardiac angiotensin levels measured in vivo, with the use of appropriate prior purification and separation (Ang I, Ϸ5 fmol/g wet wt; Ang II, Ϸ20 fmol/g wet wt), 47, 48, 49, 50 even levels of 5 to 10 fmol/mL are very high, because in most studies, medium was collected from only 1 to 10 million cells, with an estimated wet weight far below 1 g. Sadoshima et al 77 found the Ang II concentration in the medium of serum-deprived cardiomyocytes to increase nearly 100-fold on stretch. This Ang II, which is assumed to be responsible for the hypertrophic 59, 77, 79, 80 or apoptotic 81 response of cardiomyocytes after stretch, appeared to originate from intracellular storage sites, inasmuch as its release was not affected by captopril and not accompanied by Ang I release. 77 Immunoelectron microscopy confirmed the existence of secretory granule-like structures containing Ang II in ventricular cardiomyocytes. 77 Dostal et al 78 did not observe these granulelike structures and localized intracellular Ang II in the perinuclear region of neonatal rat cardiomyocytes and fibroblasts. Stretch is assumed to cause an upregulation of RAS components in cardiomyocytes, 80, 81 and this would explain why the Ang II levels in the medium are also elevated 20 to 24 hours after the initiation of stretch. 81 However, the reports on elevated renin and ACE mRNA levels were not supported by protein measurements, 77, 79 suggesting that increases in expression may not be translated to the protein level. In addition, not all authors were able to observe a rise in Ang II after stretch. 58, 59 Taken together, therefore, the initial report by Sadoshima et al on Ang II release after stretch has not been unequivocally confirmed by others. It is possible that differences in experimental conditions have played a role. Furthermore, the Ang II in intracellular storage sites may have been derived, via AT 1 receptor-mediated endocytosis, 51 from the serum-containing medium used to culture the cells before stretch.
Effect of Ang II on Heart Cell-to-Cell Coupling
Ang II regulates intercellular communication in cardiac muscle. 82 For instance, in hearts of normal adult rats and cardiomyopathic hamsters, at a late stage of the disease, Ang II administered to the extracellular fluid reduces gap junction conductance within seconds. 83, 84 This effect, which was blocked by losartan, is dependent on activation of PKC because it was abolished by staurosporine. 84, 85 In the failing hamster heart, enalapril increased junctional conductance by 219Ϯ20%. 84 Although the mechanism of action of enalapril on cell coupling is not known, its effect on junctional conductance may be responsible, at least in part, for the increment in conduction velocity that is normally seen with ACE inhibitors in cardiac muscle of the failing heart. 85 Furthermore, this effect might play a role in the prevention of slow conduction and reentry, 2 major factors involved in the generation of cardiac arrhythmias. 86 Is an Intracrine RAS Involved in the Regulation of Heart Function?
We investigated the role of an intracrine RAS in the regulation of intercellular communication by using ventricular myocytes from rats and hamsters. 23, 84, 87, 88 Renin or Ang I dialyzed into cell pairs of adult rats caused a decrease in junctional conductance, 23 and the effect of renin was appreciably increased by simultaneous administration of angiotensinogen. 87 The effect of intracellular Ang I on cell coupling is related to its conversion to Ang II, because enalaprilat administered to the cytosol reduced the effect of Ang I. Moreover, Ang II, when administered to the cytosol, reduced the junctional conductance by 60% within 45 seconds. 23 The latter effect was suppressed by intracellular administration of losartan, suggesting that it is related to the activation of a receptor similar to the AT 1 receptor. 23 In myocytes from cardiomyopathic hamsters, intracellular dialysis of Ang I also caused suppression of cell communication, and this effect was again drastically reduced by intracellularly added enalaprilat. 84 In myocytes from adult rats, in which Ang II has a negative inotropic action, intracellular administration of Ang II reduced the inward Ca 2ϩ current, whereas in myocytes from adult hamsters, in which Ang II exerts a positive inotropic effect, the opposite was found. 88 In this respect, it is of interest to note that in nondifferentiated hybrid NG108-15 cells (neuroblastomaϫglioma), Ang II, through AT 2 receptor stimulation and activation of protein tyrosine phosphatase, decreases T-type Ca 2ϩ current, 89 whereas in adrenal glomerulosa cells, Ang II, through AT 1 receptor stimulation and activation of a G i protein, increases T-type Ca 2ϩ channel current. 90 Finally, Ang II causes rapid alkalinization in cultured neonatal rat ventricular myocytes. This effect did not involve the Na ϩ -H ϩ exchanger and could be blocked by PD123319, suggesting that it is AT 2 receptor-mediated. 91 Alkalinization might be related to the effects of Ang II on cardiac contractility but does not explain the decline in cell communication induced by Ang II in myocytes, because alkalinization increases cell coupling (see Reference 82) .
In summary, Ang II, when added extracellularly, reduces cell coupling and conduction velocity in cardiac muscle. ACE inhibitors exert opposite effects. When administered intracellularly into cardiac myocytes, Ang II also reduces cell coupling and controls inward Ca 2ϩ current, possibly through stimulation of an intracellular AT 1 receptor. Intracellular Ang II may be derived from the extracellular space, through AT 1 receptor-mediated endocytosis. 51 Alternatively, Ang II may have been synthesized intracellularly, 57 for instance, by plasma-derived renin that, after its diffusion into the interstitial space, 56, 60, 74 has been internalized by myocytes. 63 Taken together, these findings support the existence of an intracrine RAS that is involved in the regulation of heart contractility and impulse propagation.
